COVID-19

TMS for the treatment of neuropsychiatric symptoms in patients with long COVID appeared to improve their cognitive function and symptoms of depression.

What is new in research on SUDs?

According to research, 32% of patients said they did not typically receive care via their preferred method, and nearly half (45%) did not think their clinician considered their preferences when deciding on the visit type.

Get ready for our upcoming virtual, interactive conference with some highlights from 2022.

What is new in research on psychedelics?

From the efficacy of adjunctive TMS for treatment-resistant major depression to a look at adult ADHD, here are highlights from the week in Psychiatric Times.

Let’s take another look at telepsychiatry.

From new research on psilocybin as a treatment for MDD to new FDA approvals for ADHD and BED, here are highlights from the week in Psychiatric Times.

The experts weighed in on a wide variety of psychiatric issues for the August 2023 issue of Psychiatric Times.

How can clinicians recognize and acknowledge the injustices often experienced by COVID long-haulers?

From the brain-gut connection to neurocognitive and neuropsychiatric symptoms of long COVID, here are highlights from the week in Psychiatric Times.

"With the similarities observed in neurocognitive and neuropsychiatric symptoms of long COVID and concussion/mTBI, approaches to effectively manage concussion/mTBI may provide some insights to treatment."

From TMS as a treatment for long COVID to an update on 988 and crisis care, here are highlights from the week in Psychiatric Times.

Did you miss our APA Annual Meeting coverage?

Our 5 senses… are they under attack?

Many individuals infected with COVID-19 continue to experience symptoms after recovering from the initial viral infection. Persistent symptoms include neurocognitive and neuropsychiatric symptoms that can interfere with meaningful daily activities and roles. Given the symptom overlap, best practices and evidenced-based techniques for the treatment of concussion/mTBI can inform treatment approaches to manage symptoms and reduce the negative impact of long COVID.

The experts weighed in on a wide variety of psychiatric issues for the May 2023 issue of Psychiatric Times.

Research explores the differences between new-onset psychosis in patients with infection versus healthy controls.

From the relationship between social media and self-diagnosis to the FDA approval of the first treatment for agitation associated with Alzheimer disease dementia, here are highlights from the week in Psychiatric Times.

"It is essential to have an aggressive path forward to increase public awareness of mental health and illness, education on early intervention and treatment access, and continued destigmatization of mental illness."

Individuals with schizophrenia have experienced an increase in psychiatric, medical, and treatment risks because of the COVID-19 pandemic.

From collaborative care for individuals with schizophrenia and COVID-19 to strategies for building patient rapport, here are highlights from the week in Psychiatric Times.

How can patient-centered, collaborative care help promote safety and stabilization in the treatment of patients with cooccurring diagnoses of schizophrenia and COVID-19?

Catch up on the latest CMEs in Psychiatric Times.

How can we help primary care providers effectively manage mental health conditions in primary care settings?

It’s been 3 years since COVID-19 was declared a pandemic…

A patient loss does not undo or discard the multitude of meaningful life changing and life preserving work done.

“Bringing us home, To ourselves, Our selves, Our bodies, our shelters…”

We need to emphasize love over hate...

Which innovations can improve measurement, technology, investment, and public policy surrounding brain health?